880080-65-9

Upstream product

• 848186-86-7 N-acetonyl-4-methylbenzamide 
• 848186-85-6 c-5-[5-Acetyl-5-(p-toluoylamino)pentyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 377732-35-9 methyl 2-methyl-c-5-{4-[5-methyl-2-(4-methylphenyl)-1,3-thiazol-4-yl]butyl}-1,3-dioxane-r-2-carboxylate 
• 377732-34-8 methyl c-5-{4-[1,5-dimethyl-2-(4-methylphenyl)imidazol-4-yl]butyl}-2-methyl-1,3-dioxane-r-2-carboxylate 
• 377731-40-3 methyl 2-methyl-c-5-{4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl}-1,3-dioxane-r-2-carboxylate 

Relevant academic research and scientific papers

Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists

A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydropho

Heterocyclic compounds

The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R1-Het-D-E??[1] wherein: R1